Calidi Biotherapeutics CLDI
NYSE CLDI
$0.76 -0.01 (-1.31%)
As of: Oct 21, 2026 · 3:46 PM EDT

Calidi Biotherapeutics (CLDI) Receivables (2022 - 2023)

Updated

Calidi Biotherapeutics (CLDI) recorded Receivables of $870.00 in Q2 2023.

Analysis

Calidi Biotherapeutics (CLDI) Receivables (2022 - 2023) Analysis & Trends

At the end of FY2022, Calidi Biotherapeutics reported Receivables of $1,740.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 19.05 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 13.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 15.68 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 12.49 Bn
10 Calidi Biotherapeutics 1.08 Mn -24.30 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 870.00
Dec 31, 2022 1,740.00
API Access

Calidi Biotherapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=CLDI&period=max&api_key=YOUR_API_KEY